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The four dengue virus (DENV) serotypes are mosquito-borne flavivi-
ruses of humans. The interactions between DENVs and the human
host that lead to asymptomatic, mild, or severe disease are poorly
understood, in part, because laboratory models are poor surrogates
for human DENV disease. Virologists are interested in how the
properties of DENVs replicating in people compare with virions propa-
gated on laboratory cell lines, which are widely used for research
and vaccine development. Using clinical samples from a DENV type 1
epidemic in Sri Lanka and new ultrasensitive assays, we compared
the properties of DENVs in human plasma and after one passage on
laboratory cell lines. DENVs in plasma were 50- to 700-fold more
infectious than cell culture-grown viruses. DENVs produced by labora-
tory cell lines were structurally immature and hypersensitive to
neutralization by human antibodies compared with DENVs circulat-
ing in people. Human plasma and cell culture-derived virions had
identical genome sequences, indicating that these phenotypic differ-
ences were due to the mature state of plasma virions. Several dengue
vaccines are under development. Recent studies indicate that vaccine-
induced antibodies that neutralized DENVs in cell culture assays were
not sufficient for protecting people from DENV infections. Our results
about structural differences between DENVs produced in humans
versus cell lines may be key to understanding vaccine failure and
developing better models for vaccine evaluation.
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Several hundred million people are infected each year by thefour dengue virus (DENV) serotypes, which are mosquito-
mixture of immature, partially mature, and fully mature virions
containing variable amounts of unprocessed prM (7, 8). Recent
studies have also established that the viral envelope is quite flexible
in some laboratory strains of DENV. This phenomenon, termed
virus breathing, is influenced by temperature and specific mutations
on E protein (9, 10). Both the maturation state of DENVs and the
flexibility of the envelope can have profound effects on the ability
of mAbs and human immune sera to neutralize the virus (11–13).
While a rich body of work has emerged from these structure and
function studies of DENVs used in the laboratory, no systematic
studies have been done to compare the properties of DENVs
propagated using cell lines and DENVs produced in infected people.
This is a major gap in our knowledge, especially given recent reports
from vaccine trials that many people were susceptible to DENV in-
fections despite vaccines inducing antibodies that neutralized DENVs
in cell culture assays (14). The goal of our study was to compare the
structural and functional properties of dengue virions circulating in
people and virions propagated using laboratory cell lines.
Significance
Due to difficulty in obtaining relevant samples and low levels
of dengue virus (DENV) present in patients, it has been difficult
to characterize the properties of virions circulating in humans.
We characterized DENV1 directly from early acute primary den-
gue samples and from their cell culture isolates. We observed
that virions in humans are more infectious and mature as com-
pared with their cell culture isolates. DENV1 cell culture isolates
were hypersensitive to neutralization by human antibodies. Cross-
reactive fusion loop antibodies and heterotypic immune sera
poorly neutralized plasma DENV1. Identical genome sequences
showed that the phenotypic differences are due to the differ-
ences in maturation state. The observed structural variation is
a significant advance applicable to understanding vaccine
failure and designing future vaccine strategies.
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borne flaviviruses responsible for dengue fever (DF) and severe 
dengue hemorrhagic fever (DHF) (1). Infection with any DENV 
serotype confers lifelong immunity against the infecting serotype 
but not against heterologous serotypes (2). While the pathogenesis 
of severe dengue disease is incompletely understood, a key de-
terminant is the ability of some antibodies to enhance the rep-
lication of DENVs in infants born to DENV-immune mothers and 
older individuals experiencing secondary DENV infections (3, 4). 
DENV-specific antibodies and T cells protect people from DENV 
infection and disease (reviewed in ref. 5). With existing laboratory 
models to study DENVs, it has been challenging to define inter-
actions between the virus and human host that suppress or promote 
DENV replication in people. In this study, we explore whether 
structural differences between DENVs circulating in patients and 
virions produced under laboratory conditions impede current ef-
forts to study dengue pathogenesis and develop vaccines.
The dengue virion contains two integral membrane proteins 
designated as envelope (E) and premembrane (prM). During 
virus secretion from infected cells, prM is cleaved to generate 
mature infectious virions, which have a smooth surface of 90 
antiparallel E dimers that are tightly packed to form a protein 
coat with icosahedral symmetry (6). In laboratory cell lines com-
monly used to propagate DENVs, prM processing is inefficient 
and variable, and virions released from cells are a 
heterogeneous
Here, we show that DENV1 circulating in patients is more
infectious and mature than cell culture isolates. Cross-reactive
dengue antibodies and heterotypic dengue immune sera poorly
neutralize plasma DENV1 compared with cell culture-produced
virus. Our results are directly relevant to evaluating vaccines in
the current pipeline and for developing new vaccines.
Results
To study the properties of DENVs circulating in humans, we
collected blood from patients suspected of having DF during a
DENV1 epidemic in Sri Lanka in 2014. Samples collected during
the febrile period (1–4 d after onset of fever) were tested by RT-
PCR to detect acute DENV1 infections. Blood samples from six
positive subjects who had acute infections were selected for the
current study.
DENVs Circulating in Patients Are More Infectious than DENVs
Produced in Cell Culture. To compare the specific infectivity of
DENV1 virions circulating in patients and virions released by
laboratory cell lines, we infected Vero (mammalian) and C6/36
(mosquito) cells using plasma from each viremic subject (Fig. 1A).
To calculate specific infectivity, we measured the number of infec-
tious virions and the number of viral genome copies in each plasma
sample and the corresponding clarified cell culture supernatants
(SI Appendix, Table S1). The number of infectious virions was
measured by focus assay (SI Appendix, Fig. S1), and the number
of viral genomes was measured by digital drop RT-PCR. Viral-
specific infectivity was expressed as the number of infectious virions
per genome copy. The low-passage (P1) clinical isolates of DENV1
from Sri Lankan patients harvested from C6/36 and Vero cell
culture media contained, on average, 2.0 × 105 and 1.6 × 104 viral
genome copies per infectious virion (Fig. 1B and SI Appendix, Table
S1). In contrast, DENV1 virions in human plasma were signifi-
cantly more infectious and contained, on average, only 2.8 × 102
viral genomes per infectious unit (Fig. 1B and SI Appendix, Table S1).
Thus, the plasma DENV1 virions were rendered 725-fold less in-
fectious after a single passage on C6/36 insect cells and 56-fold less
infectious after a single passage on Vero cells.
DENVs Circulating in Patients Are More Mature than DENVs Produced
in Cell Culture. We next characterized the maturation state of
DENV1 virions in human plasma and cell culture media using an
antibody to detect unprocessed prM protein on virions. Blood
samples from four subjects who had serological profiles indicative of
primary DENV1 infections were selected for the rest of the study.
We excluded people with secondary DENV1 infections because
preexisting DENV-binding antibodies in the acute samples could
interfere with the assays to characterize virions. To check matura-
tion state, we incubated virus samples with magnetic beads con-
taining mAbs that bound to prM protein (2H2) or DENV E protein
(1M7) and then measured the fraction of infectious virions that
were not removed by the mAb-coated beads. In theory, all virions in
each specimen should be removed by beads containing the 1M7 E
protein-specific mAb, whereas only prM containing partially and
fully immature virions should be depleted with the 2H2 prM-
specific mAb. This approach was first validated using virions of
defined maturation state produced in the laboratory (SI Appendix,
Fig. S2). DENV1 virions in human plasma were efficiently removed
by the E-specific 1M7 mAb but not by the prM-specific 2H2 mAb
(Fig. 2 and SI Appendix, Fig. S3). In contrast, the majority of P1
clinical isolates in C6/36 and Vero cell culture supernatants were
removed by the 2H2 prM mAb (Fig. 2 and SI Appendix, Fig. S3).
The prM antibodies bind to partially mature DENVs and enhance
infection of Fc receptor-bearing cell lines (7). As an alternate method
for detecting low levels of prM protein on virions, we performed
prM antibody enhancement assays with human plasma and Vero
cell-derived DENV1 samples (SI Appendix, Fig. S4). The prM an-
tibodies readily enhanced Vero cell-derived virions but not human
plasma-derived virions, confirming the absence of prM protein on
plasma virions. We conclude that DENV1 virions circulating in
patients are mature, whereas even a single passage in cell culture
leads to the release of virions with prM protein on the surface in-
dicative of incomplete intracellular processing.
Human Antibodies Directed to the Fusion Loop of E Protein Poorly
Neutralize DENVs Derived from Patients Compared with DENVs
Produced in Cell Culture. As the interaction of some antibodies
with DENVs is strongly influenced by subtle changes in virion
Fig. 1. Specific infectivity of DENV1 virions pro-
duced in people and laboratory cell lines. (A) Plasma
from six subjects experiencing primary DENV1 infec-
tions was used to infect C6/36 and Vero cells. Viral-
specific infectivity in human plasma and cell culture
supernatants (Vero and C6/36 cells) was estimated
by dividing the number of infectious virions by the
number of viral genomes in each sample. (B) Specific
infectivity of DENV1 viruses in human plasma and
respective cell culture isolates. Cell culture virions are
color-coded to match their respective plasma virus
sample. Infectious virus titers and viral genome copies
were the results of average values from two techni-
cal replicates in a single experiment. Specific infectiv-
ity for each virus was calculated from the above-
calculated average values. Lines indicate the mean.
Two-way ANOVA with a Tukey’s multiple compari-
sons test was performed to compare specific infectiv-
ity differences among plasma DENV1 samples and their
cell culture isolates.
epitopes near the fusion loop efficiently neutralized virions released
by regular Vero cells and failed to neutralize the mature virions
released by the furin-overexpressing Vero cells, reverting the
neutralization phenotype similar to that obtained from plasma
virions (Fig. 3 G and H). These results support the hypothesis
that DENVs produced on standard laboratory cells are hypersensi-
tive to neutralization by some human cross-reactive antibodies
because they are more immature compared with virions circulating
in people.
Heterotypic DENV Human Immune Sera Poorly Neutralized Plasma
DENV1. Next, we performed studies to compare the ability of
human DENV immune sera to neutralize plasma and cell culture-
derived virions. A panel of immune sera from people who had
recovered from primary DENV1 infections (homotypic immune
sera) or primary DENV2 or DENV3 infections (heterotypic
immune sera) (SI Appendix, Table S3) was used for the experi-
ments. The four homotypic immune sera strongly neutralized both
the plasma [mean neutralization 50 (Neut50) = 1,588] and cell
culture-derived (mean Neut50 = 10,306) DENV1 virions (Fig. 4A).
On average, the homotypic immune sera neutralized the cell culture-
derived virions about sixfold better than the plasma viruses (Fig. 4C).
When heterotypic primary immune sera from DENV2 and
DENV3 infected individuals were tested against DENV1, we ob-
served strong neutralization of cell culture-grown P1 virus (mean
Neut50 = 1,025) and very low to undetectable neutralization of
plasma virus (mean Neut50 = 81) (Fig. 4B). On average, heterotypic
immune sera neutralized cell culture virus 13-fold better than plasma
virus (Fig. 4C). These results establish that a single passage in cell
culture generates virions that are hypersensitive to neutralization by
heterotypic primary immune sera. In contrast, the homotypic im-
mune sera efficiently neutralized DENV1 virions irrespective of
their human plasma or cell culture origin. When we controlled for
maturation state by producing DENV1 in furin-overexpressing
Vero cells, plasma and Vero (furin)-derived virions were equally
sensitive to neutralization by human immune sera (Fig. 4A, B, andD).
DENV1 Produced in Humans and in Cell Culture Have Nearly Identical
Genomes. The structure of DENVs released from infected cells
will depend on the genome of the virus as well as posttranslational
Fig. 2. Maturation state of DENV1 virions in human
plasma and cell culture supernatant. DENV1 virions
in clinical and cell culture samples were depleted us-
ing magnetic beads coated with E-specific mAb 1M7,
prM-specific mAb 2H2, and DENV3 type-specific mAb
8A1 (control depletion). After removal of specific virus
populations using mAb-coated magnetic beads, the
remaining infectious virions were detected using a
Vero cell-based infectious focus assay. Depletion of
SJT008 DENV1 from human plasma (A and D) and
corresponding P1 clinical isolates from C6/36 (B and E)
and Vero (C and F) cells are shown. The percentage of
infectious virions remaining after depletion was cal-
culated from three technical replicates in a single ex-
periment. Error bars indicate the range of the three
technical replicates. Compiled depletion data for DENV1
from four plasma samples (SJT008, SJT003, SJT001, and
SJT004) (G) and their isolates in C6/36 (H) and Vero (I)
cells are shown. Samples are color-coded to match cor-
responding plasma samples. (D–I) All measurements are
normalized to the corresponding control-depleted
(C) sample. Two-way ANOVA was performed to com-
pare depletion variations within plasma DENV1 sam-
ples and their clinical isolates in C6/36 and Vero cells.
Lines indicate the mean.
structure, including maturation state, we compared the ability of 
a panel of well-characterized human mAbs (SI Appendix, Table 
S2) to neutralize DENV1 virions circulating in people and pro-
duced by laboratory cell lines (15–18). The 14C10 mAb is a 
DENV1 type-specific and strongly neutralizing human mAb 
isolated from a DENV1 case, whereas EDE2 B7 is a DENV 
serotype cross-reactive and strongly neutralizing mAb isolated 
from a secondary DENV case (16, 18). The 14C10 and EDE2 B7 
mAbs recognize quaternary-structure epitopes centered on do-
main 1 of E protein (EDI) and the hinge region between EDI 
and EDII, respectively (16, 18). Both 14C10 and EDE2 B7 ef-
fectively neutralized human plasma (EC50 = 43–154 ng/mL) and 
the corresponding C6/36 and Vero cell culture-derived DENV1 
virions (Fig. 3 A and B). The C6/36 and Vero cell-derived viruses 
were neutralized two- to 20-fold more efficiently than plasma 
viruses by these human mAbs. Human mAbs 1M7 and 1C19 bind 
to highly conserved, simple epitopes near the fusion loop on 
EDII (17). These antibodies poorly neutralized plasma virions 
(EC50 ∼ 300–1,800 ng/mL) compared with cell culture-derived 
DENV1 virions (Fig. 3 C and D). We conclude that some hu-
man mAbs, especially those targeting conserved epitopes near 
the fusion loop on EDII, are effective at neutralizing cell culture-
derived virions but not virions circulating in infected people. On 
the other hand, mAbs directed to quaternary epitopes near EDI 
efficiently neutralized both plasma and cell culture-derived 
DENV1 virions.
Mature Virions Are Poorly Neutralized by Cross-Reactive Fusion Loop 
Antibodies. Cell culture-derived virions may be more sensitive 
than plasma virions to fusion loop antibodies because the fusion 
loop is more exposed in immature cell culture virions compared 
with plasma virions. To test this hypothesis, we used the DENV1 
clinical isolate from patient SJT008 to infect regular and furin 
protease-overexpressing Vero cells. The virions released from 
furin-overexpressing cells were more mature than virions released 
from regular Vero cells (SI Appendix, Fig. S6 A and B). Quaternary 
epitope human mAbs 14C10 and EDE2 B7 efficiently neutralized 
virions released by regular and furin-overexpressing Vero cells (Fig. 3 
E and F). On the other hand, two human mAbs targeting conserved
of N-linked glycans), and binding of human plasma factors to vi-
rions may contribute to the observed differences in specific in-
fectivity between human plasma and cell culture DENVs.
Virions in human plasma and cell culture had nearly identical
genome sequences, excluding strong selective pressure as an
explanation for phenotypic differences. Laboratory cell lines are
likely to release immature virions because the robust replication
of DENVs will overwhelm the host furin protease in the Golgi
that cleaves prM to generate mature virions. In support of this
model, we observed that Vero cells engineered to overexpress
furin released DENVs that were more mature than DENVs
released from regular Vero cells. While the precise cells that
produce DENVs in people have not been defined well, the level
of viral replication and furin protease expression in human target
cells may lead to efficient prM cleavage and only the release of
mature virions. In people, DENVs have been observed in various
organs such as the spleen, lymph nodes, liver, and lungs and
found to infect phagocytes (including blood monocytes, tissue
macrophages, and dendritic cells) and hepatocytes (reviewed in
refs. 21, 22). In a recent comprehensive histological study of
tissues from 13 fatal cases of DHF/dengue shock syndrome
(DSS) in children, DENV infection was confirmed in hepato-
cytes and Kupffer cells in the liver and in macrophage-like cells
in spleens and lymph nodes (23). Within germinal centers, the
investigators noted a reduction in lymphocytes and an increase in
eosinophilic deposits containing dengue antigens, immunoglobulins,
and complement components. Recently, investigators have also
reported on the presence of atypical DENVs present in infectious
vesicles derived from CD61+ cells of the megakaryocyte lineage in
human plasma (24, 25). Further studies are needed to fully define
the human target cells.
Fig. 3. Neutralization ability of human mAbs against plasma and cell culture DENV1. (A–D) Various dilutions of human mAbs were used to neutralize DENV1
viruses from plasma and their C6/36 and Vero cell culture clinical isolates. Neutralization curves for human mAbs were plotted using GraphPad Prism
(SI Appendix, Fig. S5). This figure shows the compiled neutralization data of human mAbs for DENV1 from three plasma samples (SJT008, SJT003, and SJT004)
and their isolates in C6/36 and Vero cells. Lines indicate the mean. Two-way ANOVA with a Tukey’s multiple comparisons test was performed to compare the
plasma DENV1 with C6/36 and Vero cell culture isolates. (E–H) Various dilutions of human mAbs were used to neutralize DENV1 viruses from plasma and their
Vero and furin-overexpressing Vero (Vero furin) cell culture clinical isolates. Neutralization curves for human mAbs were plotted using GraphPad Prism. Each
data point is the mean of percent neutralization for two technical replicates in a single experiment. Error bars indicate the range of two technical replicates.
processing events dictated by the infected cells. To determine if 
laboratory cell lines selectively amplified plasma virions that were 
genetically different from the dominant population circulating in 
people, we sequenced the entire viral genome present in two plasma 
samples and the corresponding P1 viruses amplified on Vero and 
C6/36 cells from two different sources. The consensus sequences 
of the plasma and P1 viruses were nearly identical, except for a 
few minority variants in cell culture P1 viruses that did not map 
to DENV1 structural proteins (SI Appendix, Table S4). Based on 
this analysis, we conclude that the structural differences between 
DENV1 virions circulating in people and after a single passage on 
cell lines are caused by the actual infected target cells producing 
virions, and not viral genetic differences.
Discussion
We have demonstrated that a single passage in cell culture has a 
major impact on the structural and functional properties of 
DENVs circulating in people. DENVs in human plasma were 
fully mature, whereas most virions released by laboratory cell 
lines were immature and contained unprocessed prM protein on 
the surface. Vogt et al. (19) have reported that West Nile virus 
(WNV) circulating in mice was more mature than virions pro-
duced by C6/36 insect cells. In the same study, the investigators 
noted that WNV generated in Vero cells had a mature pheno-
type that was similar to virions circulating in mice. Therefore, 
WNV appears to be different from DENV1 with respect to the 
efficiency of prM processing in Vero cells. It is well documented 
that mature virions are more infectious than partially or fully im-
mature virions because unprocessed prM bound to E protein in-
hibits viral fusion required to infect cells (20). In addition to 
maturation state, other factors such as the lipid composition, post-
translational modifications (including addition and 
processing
mAbs and homotypic DENV1 immune sera and poorly neutralized
by fusion loop mAbs and heterotypic human immune sera.
The highly successful yellow fever and Japanese encephalitis
vaccines establish the importance of vaccination for protecting
people from flavivirus infections. For both of these attenuated
live-virus vaccines, neutralizing antibodies are strongly corre-
lated with vaccine efficacy. In addition to antibody responses, a
single dose of yellow fever and Japanese encephalitis vaccines
augments effective T cell immunity (27–29). DENV vaccines
faced a major setback recently in clinical trials when people
developed vaccine breakthrough infections despite developing
relatively high levels of neutralizing antibodies (14). Our results
here provide an explanation for the failure of cell culture virus
neutralizing antibodies to predict DENV vaccine efficacy. Lab-
oratory propagated, partially immature DENV virions will over-
estimate levels of protective antibodies because of their sensitivity
to heterotypic neutralizing antibodies. Indeed, we recently demon-
strated that a leading tetravalent live-attenuated DENV vaccine with
poor efficacy against DENV2 mainly induced heterotypic neutral-
izing antibodies against this serotype (30). Our results provide a
strong rationale for using fully mature virions that better represent
the structure of virions circulating in people when evaluating vaccine
immunogenicity and efficacy.
In this study, we establish the strong impact of cell culture
passage on the structure of DENVs and a rationale for developing
more relevant assays for studying pathogenesis and assessing
vaccine performance. Our study was performed using multiple
patients and isolates from a single DENV1 epidemic in Sri
Lanka. By focusing on a single epidemic and also sampling
primary cases within the first 4 d after onset of symptoms, we
were able to control for other variables such as viral serotype
and genotype, immune status of the host, and the effect of
preexisting antibodies on circulating virions. Further studies are
needed to compare people experiencing primary or secondary
Fig. 4. Neutralization ability of homotypic and heterotypic human immune sera against plasma and cell culture DENV1. Various dilutions of homotypic (SI
Appendix, Fig. S7) and heterotypic (SI Appendix, Fig. S8) human DENV immune sera were used to neutralize DENV1 from SJT008 plasma and P1 isolate from
Vero and Vero Furin cells. Neut50 values for four homotypic (A) and four heterotypic (B) sera were plotted, followed by fold differences in Neut50 between
Vero and plasma DENV1 (C), and fold difference in Neut50 between Vero and Vero Furin derived DENV1 (D). Colors represent a single serum. Lines indicates
the mean. Two-way ANOVA was performed to compare the neutralization variations for plasma DENV1 versus Vero P1 isolate among homotypic and
heterotypic dengue immune sera. Vero Furin, furin-overexpressing Vero.
We observed that human plasma and cell culture-derived DENV1 
virions were differentially neutralized by human antibodies. DENV 
cross-reactive, fusion loop-directed mAbs and heterotypic immune 
sera (from primary DENV2 and DENV3 patients) efficiently 
neutralized cell culture viruses but not the human plasma viruses. 
Indeed, several groups have demonstrated that the maturation state 
of virions produced on laboratory cell lines has a strong impact on 
the ability of some cross-reactive mAbs to neutralize DENVs (11–
13). Moreover, Mukherjee et al. (11) demonstrated that the DENV 
maturation state has a strong impact on the ability of some DENV 
vaccine-immune sera to neutralize DENVs as well. The fusion loop 
on EDII, a major target of cross-reactive antibodies, is well ex-
posed on immature virions (26). In contrast, the fusion loop is 
hidden in the head-to-tail–oriented E protein homodimers that 
cover the surface of mature virions circulating in human plasma 
(6). We conclude that poor exposure of the fusion loop on mature 
plasma virions renders them less sensitive to neutralization by cross-
reactive mAbs and heterotypic DENV immune sera.
DENV1 type-specific mAbs and DENV1 homotypic immune 
sera (from primary DENV1 cases) strongly neutralized both 
human plasma and cell culture-derived virions. However, even 
with DENV1 type-specific antibodies, we observed that cell 
culture-grown immature virions were more sensitive to neutrali-
zation than mature human plasma virions. This result was antici-
pated because immature virions contain fewer fusion-competent 
E protein homodimers than fully mature virions, leading to a lower 
threshold of neutralization by type-specific mAbs. Compared with 
mature DENV1 particles, immature particles would be more 
sensitive to neutralization by homotypic DENV1 immune sera 
because of the exposure of the fusion loop recognized by cross-
reactive antibodies and the reduced number of fusion-competent E 
molecules on immature virions. The most important finding relevant 
to protective immunity in people was that DENV1 particles in hu-
man plasma were efficiently neutralized by type-specific human
DENV infections with different DENV serotypes and geno-
types to more broadly assess the impact of virion structure on
human disease and vaccine performance.
Methods
Patient Blood Plasma. Blood samples were collected from patients suspected
of having DF in a clinical setting during the 2014 Sri Lankan DF epidemic.
More information is provided in SI Appendix, SI Methods. Ethical approval
for this research was obtained from the Ethical Review Committee of the
Faculty of Medicine, University of Colombo, Sri Lanka (serving as the in-
stitutional review board for Genetech Research Institute). The University of
North Carolina (UNC) Institutional Review Board determined that its ap-
proval was not required because participating UNC investigators were not
involved in human subject research. Only children whose parents or legal
guardians provided written informed consent were enrolled in the study.
Cells Lines and Viruses. Detailed information is provided in SI Appendix,
SI Methods.
Isolation of Virus from Clinical Samples. DENV1 clinical isolates were made in
C6/36, Vero, and furin-overexpressing Vero cells by inoculating virus from
plasma samples. More information is provided in SI Appendix, SI Methods.
Digital Drop PCR. RNA copies of DENV1 were detected in blood plasma
samples and cell culture isolates using digital drop PCR. More information is
provided in SI Appendix, SI Methods.
Vero Infectious Titer Assay. DENV1 from plasma and cell culture isolates were
serially diluted and infected on Vero cells. Cells were stained after foci for-
mation and counted manually. More information is provided in SI Appendix,
SI Methods.
Antibody-Dependent Enhancement Assay. Human anti-prM antibody was in-
cubated with DENV1 from Vero cells, furin-overexpressing Vero cells, and
plasma. The virus–antibody immune complex was infected on K562 cells and
stained after 24 h to check infection. More information is provided in SI
Appendix, SI Methods.
Depletion Assay. We used 50 μL of Dynabeads Protein G magnetic beads
(Novex) to bind 10 μg of 2H2, 1M7, and 8A1 mAbs according to the manu-
facturer’s protocol. Briefly, magnetic beads and mAbs were kept at room
temperature for 1 h in a rotator for binding. Unbound mAbs were removed
by applying the magnet and removing the supernatant. PBS was used to wash
remaining unbound mAbs. About 50 infectious units of virus was captured
in triplicate with mAb bound to magnetic beads by keeping them at room
temperature for 1 h in a rotator. Unbound virus was used to infect a Vero
cell monolayer grown for 48 h in a 24-well plate. Plates were incubated and
stained as explained above. Undepleted control was kept for processing dur-
ing the assay. An equal amount of normal human plasma was spiked in cell
culture virus while performing the assay.
Neutralization Assay. Various dilutions of mAbs or sera were incubated with
DENV1 from plasma and cell culture isolates and infected on Vero cells. Cells
were stained after foci formation and countedmanually. More information is
provided in SI Appendix, SI Methods.
Library Preparation and Sequencing Plasma and Cell Culture DENV1. Viral RNA
was isolated from human plasma samples and their cell culture isolates.
Sequencing libraries were prepared, and sequencing was performed on Illumina
systems. More information is provided in SI Appendix, SI Methods.
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